Gewinn- und Verlustrechnung von GRAIL Inc.

GRAIL NASDAQ: GRAL Chief Financial Officer Aaron Freidin said the company's Galleri multi-cancer early detection test recorded strong first-half growth as it expanded distribution through digital health platforms, employers and physician offices.

Bank of America Corp DE raised its holdings in shares of GRAIL, Inc. (NASDAQ: GRAL) by 29.0% during the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 914,114 shares of the company's stock after purchasing an additional 205,611 shares

GRAIL faces a binary FDA approval event for Galleri, with significant stock movement expected based on the outcome. Despite disappointing NHS-Galleri trial results, I believe the true value of the test would have been apparent with a longer monitoring period. While GRAL has a solid cash position, commercialization delays could see the company having to raise a large amount of capital on unfavorable terms.

GRAIL Inc. (NASDAQ:GRAL) on Friday said it is preparing for a pivotal regulatory event as the U.S. Food and Drug Administration's (FDA) Molecular and Clinical Genetics Panel gears up to evaluate the healthcare company's flagship cancer diagnostic tool.

GRAIL Announces FDA Advisory Committee Meeting to Review Premarket Approval Application for the Galleri Multi-Cancer Early Detection Test

Grail said on Friday the U.S. FDA ​plans to hold a ‌meeting of outside experts to review its multi-cancer screening test Galleri ​in September, sending its ​shares up 4% in morning ⁠trade.

MENLO PARK, Calif., Aug. 7, 2026 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that the U.S. Food and Drug Administration's (FDA) Molecular and Clinical Genetics Panel of the Medical Devices Advisory Committee is scheduled to meet on Sept.

GRAIL, Inc. (GRAL) Q2 2026 Earnings Call Transcript

GRAIL NASDAQ: GRAL reported second-quarter revenue growth driven by higher Galleri test volumes, while outlining continued efforts to secure FDA approval, expand its commercial organization and build international distribution partnerships.

Q2 Galleri ® Test Volume Increased 35% to More Than 61,000 Year-Over-Year, and Galleri Revenue Grew 24% to $42.6 Million Galleri Test Volume and Revenue are up 42% and 30% Year-Over-Year, Respectively, for the First Half of the Year NHS-Galleri and PATHFINDER 2 Study Results Presented at 2026 ASCO Annual Meeting Demonstrated Consistent Strong Performance and Clinical Utility for Galleri Completed $110 Million Equity Financing With Samsung MENLO PARK, Calif., Aug. 5, 2026 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today reported business and financial results for the second quarter of 2026.